• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SAVOLITINIB Drug Record

  • Summary
  • Interactions
  • Claims
  • SAVOLITINIB chembl:CHEMBL3334567

    Alternate Names:

    HMPL-504
    AZD-6094
    VOLITINIB
    SAVOLITINIB
    AZD6094
    chembl:CHEMBL3334567
    drugbank:12048
    chemidplus:1313725-88-0
    pubchem.compound:68289010

    Drug Info:

    (3 More Sources)

    Publications:

    Li et al., 2017, Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer., Clin. Cancer Res.
    Choueiri et al., 2017, Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer., J. Clin. Oncol.
    Schuller et al., 2015, The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models., Clin. Cancer Res.
    Bahcall et al., 2016, Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer., Cancer Discov
    Lee J et al., 2019, Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial., Cancer Discov
  • SAVOLITINIB   MET

    Interaction Score: 2.94

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type resistant
    Approval Status Preclinical - Cell culture

    PMIDs:
    28396313 28644771 25779944 27694386 31315834


    Sources:
    JAX-CKB ChemblInteractions COSMIC CIViC TTD

  • SAVOLITINIB   EGFR

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy AZD9291 + Savolitinib
    Indication/Tumor Type lung adenocarcinoma
    Response Type sensitive

    PMIDs:
    27694386


    Sources:
    JAX-CKB

  • JAX-CKB: Savolitinib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Bahcall et al., 2016, Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer., Cancer Discov
    Choueiri et al., 2017, Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer., J. Clin. Oncol.
    Schuller et al., 2015, The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models., Clin. Cancer Res.

  • CIViC: SAVOLITINIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Lee J et al., 2019, Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial., Cancer Discov
    Bahcall et al., 2016, Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer., Cancer Discov

  • TTD: Savolitinib

    • Version: 2020.06.01

    Alternate Names:
    D0LW0T TTD Drug ID

    Drug Info:

    Publications:

  • TTD: Volitinib

    • Version: 2020.06.01

    Alternate Names:
    D04QEC TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL3334567

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL3545336

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • COSMIC: Savolitinib

    • Version: 4-Sep-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21